Tirzepatide has emerged as a promising option for treating obesity. In clinical trials, tirzepatide has been shown to result in significant weight loss compared to a placebo while also improving key metabolic markers such as blood pressure, lipid profiles, and insulin resistance. Moreover, GLP1 has been associated with a lower risk of cardiovascular events in individuals with obesity, highlighting potential advantages beyond weight reduction. This medication presents a valuable new alternative for people struggling with obesity, particularly for those who have not found success through lifestyle changes alone.Included is 1 vial which lasts 4-5 weeks depending on dose, needles and supplies, and overnight refrigerated shipping